Head-to-head · WeighScore
10rx vs Omada Health
The verdict
10rx takes it — 66.1/100 to 55.6/100.
10rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. 10rx is a nationwide GLP-1 telehealth program offering compounded weight-loss medication at low flat monthly rates: semaglutide at $99.67/month and tirzepatide at $149.67/month, with NAD+ and sermorelin…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | 10rx | Omada Health |
|---|---|---|
| WeighScore | 66.1/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #199 | #435 |
| Semaglutide | $100/mo (compounded) | Not disclosed |
| Tirzepatide | $150/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #199 · C
Strengths
- Very low pricing — compounded semaglutide $99.67/month and tirzepatide $149.67/month
- Free online health quiz with board-certified telehealth doctors reviewing eligibility
- Offers NAD+ and sermorelin alongside GLP-1, for energy and muscle recovery
- Says it ships to all 50 states with discreet delivery from licensed pharmacy partners
Where it loses points
- Doesn't publish its legal operating entity, so accountability is hard to verify
- Pharmacy partners are described as licensed but none are named
- No terms-of-service page is posted, and FAQ answers load only via script
- Compounded semaglutide and tirzepatide only — no brand-name or oral options
- No LegitScript or third-party accreditation is shown on the site
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.